Skip to Content
Merck
CN

SML0233

Ro 61-8048

≥98% (HPLC)

Synonym(s):

3,4-Dimethoxy-N-[4-(3-nitrophenyl)-2-thiazolyl]-benzenesulfonamide, 3,4-Dimethoxy-N-[4-(3-nitrophenyl)thiazol-2-yl]benzenesulfonamide, Ro-61-8048

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):
C17H15N3O6S2
CAS Number:
Molecular Weight:
421.45
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


Quality Level

assay

≥98% (HPLC)

form

powder

color

faintly yellow to yellow

solubility

DMSO: ≥15 mg/mL

storage temp.

2-8°C

SMILES string

COc1ccc(cc1OC)S(=O)(=O)Nc2nc(cs2)-c3cccc(c3)[N+]([O-])=O

InChI

1S/C17H15N3O6S2/c1-25-15-7-6-13(9-16(15)26-2)28(23,24)19-17-18-14(10-27-17)11-4-3-5-12(8-11)20(21)22/h3-10H,1-2H3,(H,18,19)

InChI key

NDPBMCKQJOZAQX-UHFFFAOYSA-N

Application

Ro 61-8048 has been used as a kynurenine 3-monooxygenase (KMO) inhibitor to study its effects on nicotinamide adenine dinucleotide (NAD+) concentration in hepatocytes of mice.

Biochem/physiol Actions

Ro 61-8048 is an inhibitor of kynurenine 3-monooxygenase (KMO) that increases kynurenic acid levels and reduces extracellular glutamate in the brain.
Inhibition of kynurenine 3-hydroxylase by Ro 61-8048 reduces the episodes of dystonia and dyskinesias induced by decreased levels of kynurenic acid.
Ro 61-8048 is a potent kynurenine 3-monooxygenase (KMO) inhibitor


Storage Class

11 - Combustible Solids

wgk

WGK 3



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Jean Rodgers et al.
Brain : a journal of neurology, 132(Pt 5), 1259-1267 (2009-04-03)
Human African trypanosomiasis, or sleeping sickness, is caused by the protozoan parasites Trypanosoma brucei rhodesiense or Trypanosoma brucei gambiense, and is a major cause of systemic and neurological disability throughout sub-Saharan Africa. Following early-stage disease, the trypanosomes cross the blood-brain
Arghya Ray et al.
Leukemia, 34(2), 567-577 (2019-08-30)
Our prior studies showed that dysfunctional plasmacytoid dendritic cells (pDCs) contribute to multiple myeloma (MM) pathogenesis. Specifically, pDC interactions with tumor and T/NK effector cells in the bone marrow (BM) milieu induce immune suppression and MM cell proliferation. Delineation of
Angelika Richter et al.
European journal of pharmacology, 478(1), 47-52 (2003-10-14)
The effects of the novel kynurenine 3-hydroxylase inhibitor 3,4-dimethoxy-N-[4-(3-nitrophenyl)thiazol-2-yl]benzenesulfonamide (Ro 61-8048) on severity of dystonia were examined in dt(sz) mutant hamsters, an animal model of paroxysmal dystonia, in which stress precipitates dystonic episodes. Ro 61-8048 (50, 100 and 150 mg/kg



Global Trade Item Number

SKUGTIN
SML0233-5MG04061832982397
SML0233-25MG04061832982380